All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

IntraBio's Aqneursa (levacetylleucine) wins EU approval for Niemann-Pick disease type C treatment
Small molecule, rare disease, modified amino acid, Niemann-Pick disease type C, neurological - Read more

Otsuka gains EU approval for Dawnzera (donidalorsen) targeting prekallikrein for hereditary angioedema prevention following Ph3 results
Antisense oligonucleotide, autoimmune, hereditary angioedema, prekallikrein, RNA-targeting - Read more

THE GOOD
Business Development & Partnerships

Bristol Myers Squibb, Microsoft partner on AI-powered lung cancer detection network
Technology partnership, oncology, AI/ML, diagnostics - Read more

Insilico Medicine, Hygtia Therapeutics split rights for preclinical NLRP3 inhibitor, $10M upfront, $56M milestones
Licensing deal, neurological, AI/ML, small molecule, milestone payments - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

IntraBio's Aqneursa (levacetylleucine) hits Ph3 win in Ataxia-Telangiectasia, plans immediate regulatory filings
Small molecule, neurological, rare disease, ataxia-telangiectasia, levacetylleucine - Read more

THE GOOD
Earnings & Finances

J&J targets $100B revenue for 2026, overcoming Stelara patent cliff with oncology growth
Monoclonal antibody, autoimmune, strategic, financial - Read more

THE GOOD
Fundraises

Infinitopes raises $35.1M seed total for oesophageal cancer vaccine trial preparation
Cancer vaccine, AI/ML platform, oncology, clinical-stage - Read more

BioAge raises $115M public offering, targeting metabolic diseases through aging biology
Metabolic diseases, clinical-stage, aging biology, small molecule - Read more

ErVimmune raises €17M ($19.8M) Series A, developing therapeutic vaccines targeting cancer tumors
Cancer vaccines, oncology, preclinical, cell therapy - Read more

Corvus Pharmaceuticals raises $175M public offering for Phase 3 lymphoma trials
Clinical-stage, T cell lymphoma, autoimmune, oncology - Read more

THE GOOD
Mergers & Acquisitions

Kuva Labs to acquire Lisata Therapeutics for $4 per share to gain phase 2 cancer drug certepetide
Cyclic peptide, oncology, strategic, major transaction - Read more

THE GOOD
Politics & Policy

Trump calls off February tariff threat on European countries, preserving deal with 15% pharmaceutical duties
Pharmaceuticals, tariff impact, strategic, regulatory - Read more

THE GOOD
Product Launches

ACG Packing unveils SuperPod cold-form blister technology reducing cavity sizes up to 39% at Pharmapack 2026
Pharmaceutical packaging, operational, cost reduction, sustainability - Read more

THE GOOD
Regulatory

FDA releases draft guidance allowing MRD and complete response endpoints for accelerated myeloma drug approvals
Multiple myeloma therapies, oncology, regulatory, strategic - Read more

FDA launches PreCheck pilot program to streamline US drug manufacturing facility approval process starting February 1
Manufacturing, regulatory, operational, strategic - Read more

EU Parliament adopts Critical Medicines Act with stricter stockpiling rules to reduce drug shortages
Pharmaceuticals, supply chain, regulatory, operational - Read more [Paywall]

House to vote on renewal of FDA's rare pediatric disease priority voucher program through 2029
Rare disease, regulatory, strategic, financial - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Lawsuits

J&J faces setback as court recommends allowing expert testimony in 67,500 talc cancer lawsuits
Consumer product, oncology, financial, regulatory - Read more

THE BAD
Layoffs

Curia Global closes Burlington Massachusetts facility, laying off 81 employees in drug manufacturing shutdown
Sterile drug manufacturing, operational, cost reduction, workforce reduction - Read more

THE BAD
Strategic Plans

IO Biotech explores strategic alternatives including potential merger, asset sale, or further layoffs after FDA setback
Cancer vaccine, oncology, strategic, operational, cost reduction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here